Relief Therapeutics Holding SA (RLF) | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Headlines Articles Press releases Relief Therapeutics Holding SA

Home
Companies
Relief Therapeutics Holding SA

BRIEF

published on 10/25/2024 at 07:05, 27 days 4 hours ago

Relief Therapeutics dévoile les résultats prometteurs d'une étude sur RLF-OD032

Étude Clinique RLF-OD032 Dépôt De Brevet Phénylcétonurie Absorption Des Médicaments
PRESS RELEASE

published on 10/25/2024 at 07:00, 27 days 4 hours ago

Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics reports positive study results for RLF-OD032, showing superior absorption in fasted state compared to KUVAN®, enabling flexible dosing. New patents filed for innovative PKU treatment

Study Results Relief Therapeutics RLF-OD032 Phenylketonuria Provisional Patents
BRIEF

published on 10/21/2024 at 07:05, 1 month ago

Relief Therapeutics obtient un brevet européen pour RLF-TD011

Désignation De Médicament Orphelin THÉRAPEUTIQUE DE SECOURS RLF-TD011 Brevet Européen Epidermolyse Bulleuse
BRIEF

published on 10/21/2024 at 07:05, 1 month ago

Relief Therapeutics Secures European Patent for RLF-TD011

Orphan Drug Designation Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa
PRESS RELEASE

published on 10/21/2024 at 07:00, 1 month ago

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets

Relief Therapeutics RLF-TD011 European Patent Epidermolysis Bullosa Wound Treatment
BRIEF

published on 10/08/2024 at 07:05, 1 month 13 days ago

Relief Therapeutics révèle des résultats prometteurs dans un essai clinique sur l'épidermolyse bulleuse

Essai Clinique THÉRAPEUTIQUE DE SECOURS RLF-TD011 Epidermolyse Bulleuse Diversité Du Microbiome
BRIEF

published on 10/08/2024 at 07:05, 1 month 13 days ago

Relief Therapeutics Reveals Promising Results in Clinical Trial for Epidermolysis Bullosa

Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
PRESS RELEASE

published on 10/08/2024 at 07:00, 1 month 13 days ago

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics reports promising preliminary results of RLF-TD011 clinical trial for epidermolysis bullosa, showing reduced Staphylococcus aureus and improved microbiome diversity

Microbiome Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa
BRIEF

published on 10/04/2024 at 07:05, 1 month 17 days ago

Relief Therapeutics annonce des résultats d'étude positifs pour le traitement de la phénylcétonurie

THÉRAPEUTIQUE DE SECOURS RLF-OD032 Phénylcétonurie Dichlorhydrate De Saproptérine Résultats De L'étude Clinique
BRIEF

published on 10/04/2024 at 07:05, 1 month 17 days ago

Relief Therapeutics Reports Positive Study Results for Phenylketonuria Treatment

Relief Therapeutics RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride Clinical Study Results

Accesswire

Published on 11/21/2024 at 11:30, 13 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 40 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 43 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 43 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 8 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 13 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 41 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 42 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 46 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 12 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 45 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 45 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 45 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 35 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 23 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE